run for her has always embraced the word “hope.” Hope for a test, hope for a cure, and hope that our worldwide circle of friends affected by the ovarian cancer have the courage and strength to get through their individual journeys.
On a personal note, this week has been an emotional roller coaster—I learned that one run for her friend has defeated all odds and is cancer free, while another close to our hearts has had a recurrence. For her, the journey begins again.
This all reminds me of the importance of research—and how far we’ve come. Last week brought the news of a breakthrough by Beth Y. Karlan, MD, and her team at the Cedars-Sinai Women’s Cancer Program (WCP) at the Samuel Oschin Comprehensive Cancer Institute.
Dr. Karlan and WCP researchers were part of a large national study on women’s cancers published in the journal Nature. Scientists believe their findings validate the idea that cancers are better defined by their genetic fingerprint than by the organ where they originate. This could mean that certain cancers with similar gene mutations—like some endometrial, ovarian, and breast cancers–might respond to the same treatments.
“Many developments in medicine are about treatments or tests that are only useful for a certain period of time,” said one researcher. “But this is something that will be useful 200 years from now. This is a landmark that will stand the test of time.”
You can read more on the research at nytimes.com.
I hope you will join me in congratulating Dr. Karlan and all the men and women at the WCP on their good work—and for giving us all hope for better detection and cure.
And thank you for supporting run for her—you’ve made this all possible.
All the best,
run for her Founder
To learn more about how you can support the important research underway at WCP, please visit www.runforher.com.